(Q49141898)

English

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

scientific article published on 4 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/25939894

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/25939894

1 reference

based on heuristic

inferred from title

Maciej Krzakowski

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Wolfgang Schuette

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Janusz Milanowski

10

object named as

J Milanowski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

J Vansteenkiste

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

F Barlesi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

C F Waller

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

J Bennouna

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

C Gridelli

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

E Goekkurt

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

D Verhoeven

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

A Szczesna

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

M Feurer

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

P Germonpre

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

H Lena

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

D Atanackovic

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

C Hicking

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

J Straub

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

M Picard

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

K O'Byrne

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

4 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/25939894

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1734-1740

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Integrin signaling and lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Integrins as therapeutic targets.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV219

21 January 2018

Identifiers

10.1093/ANNONC/MDV219

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939894%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49141898&oldid=1914345321"